VNDA Vanda Pharmaceuticals Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:58
Sep 08
Sep 08
VNDA imsidolimab PDUFA Dec 12, strong data
Author flags Vanda's imsidolimab for generalized pustular psoriasis with PDUFA Dec 12, citing GEMINI showing 53% skin clearance by week 4 vs 13% placebo. $328M cap, ~$170M liquidity, 14% short. Market dislikes Vanda's FDA history but the data looks interesting.
MED
11:58
Feb 12
Feb 12
Long VNDA on Feb 21 Bysanti FDA decision
The author identifies Vanda Pharma as his single stock pick among biotechs with potential milestone events this month, citing its growing commercial base with Fanapt and the recent Nereus trapitant approval for motion sickness. The key catalyst is the February 21 FDA decision date for Bysanti, a new antipsychotic for bipolar I disorder and schizophrenia, which would expand VNDA's commercial portfolio into a larger psychiatric market. He notes the company is well funded with $263.8 million, reducing near-term dilution risk, and sees multiple catalysts in 2026.
HIGH
About VNDA Investor Commentary
Across the available history and selected sources, Buzzberg tracks VNDA (Vanda Pharmaceuticals Inc.) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: u/Avish_Golakiya, u/MannerProfessional24.